• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

    41.05 +0.67 (+1.66%)
    Streaming Delayed Price Updated: 3:40 PM EDT, Sep 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,319,503
    Open 41.23
    Bid (Size) 41.02 (300)
    Ask (Size) 41.08 (300)
    Prev. Close 40.38
    Today's Range 40.49 - 44.94
    52wk Range 20.04 - 94.90
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Structure Therapeutics Advances Weight-Loss Pills With New Clinical Data ↗
    Structure Therapeutics (NASDAQ: GPCR) reports strong clinical trial data for oral weight loss candidates ACCG-2671 and aleniglipron. 
    Via Benzinga
    News headline image
    Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management
    From Structure Therapeutics Inc.
    Via GlobeNewswire

    Performance

    YTD
    -39.7%
    -39.7%
    1 Month
    -23.7%
    -23.7%
    3 Month
    -0.5%
    -0.5%
    6 Month
    -29.5%
    -29.5%
    1 Year
    +96.8%
    +96.8%

    More News

    Read More
    News headline image
    Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Announces Participation in Upcoming Investor Conferences
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Monashee Scales Back Its Bet on Structure Therapeutics ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Structure Therapeutics Stock Is Up 47%, but One Fund Just Fully Exited a $2.6 Million Position ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    3 Ways to Invest in the Growing GLP-1 Weight Loss Market ↗
    Via MarketBeat
    News headline image
    Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    The Great Metabolic Land Grab: Why Viking and Structure Have Become Big Pharma’s 'Irresistible' Targets
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Eli Lilly Secures Landmark FDA Approval for Oral Weight-Loss Pill, Sending Shares Soaring
    Via MarketMinute
    Topics Economy
    News headline image
    Main Street’s Revenge: The Great Rotation of 2026 Rewrites Market History
    Via MarketMinute
    Topics Artificial Intelligence Bonds Economy
    News headline image
    The Great Rotation: Small-Caps Seize Market Leadership in Historic 2026 Breakout
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    News headline image
    The Great Rotation: Russell 2000 Outshines Mega-Caps as Domestic Small-Caps Take the Reins in 2026
    Via MarketMinute
    Topics Artificial Intelligence Economy World Trade
    News headline image
    Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
    Via The Motley Fool
    News headline image
    3 Companies at the Forefront of the GLP-1 Pill Wars ↗
    Via MarketBeat
    News headline image
    Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
    From Structure Therapeutics Inc.
    Via GlobeNewswire
    News headline image
    Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    The Valuation Reset: A Deep-Dive into Novo Nordisk (NVO) in 2026
    Via Finterra
    Topics Economy Intellectual Property

    Frequently Asked Questions

    Is Structure Therapeutics Inc. - American Depositary Shares publicly traded?
    Yes, Structure Therapeutics Inc. - American Depositary Shares is publicly traded.
    What exchange does Structure Therapeutics Inc. - American Depositary Shares trade on?
    Structure Therapeutics Inc. - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Structure Therapeutics Inc. - American Depositary Shares?
    The ticker symbol for Structure Therapeutics Inc. - American Depositary Shares is GPCR on the Nasdaq Stock Market
    What is the current price of Structure Therapeutics Inc. - American Depositary Shares?
    The current price of Structure Therapeutics Inc. - American Depositary Shares is 41.05
    When was Structure Therapeutics Inc. - American Depositary Shares last traded?
    The last trade of Structure Therapeutics Inc. - American Depositary Shares was at 09/09/26 03:40 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.